We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
FDA Issues CRL to SNY's Regulatory Filing for Multiple Sclerosis Drug
Read MoreHide Full Article
Key Takeaways
FDA issued a CRL to Sanofi's NDA for tolebrutinib in non-relapsing secondary progressive MS.
The FDA had already extended the review timeline twice, citing additional analyses as a major amendment.
The European Commission approved SNY's Wayrilz for adult ITP patients refractory to other treatments.
Sanofi (SNY - Free Report) announced that the FDA has issued a complete response letter (CRL) to its new drug application (NDA), seeking approval for its investigational Bruton's tyrosine kinase (BTK) inhibitor, tolebrutinib. The NDA sought approval for tolebrutinib to treat adult patients with non-relapsing secondary progressive multiple sclerosis (nrSPMS).
More on FDA’s CRL for Sanofi’s Tolebrutinib
The FDA’s latest CRL for tolebrutinib does not come as a surprise, as earlier this month, the regulatory body extended the review timeline for tolebrutinib in nrSPMS for the second time this year.
Earlier this year, the FDA had extended the review period for Sanofi’s NDA for tolebrutinib in nrSPMS by three months. The FDA was initially expected to give its decision by Sept. 28, 2025. However, this date was extended by an additional three months to Dec. 28 after Sanofi’s submission of additional analyses during the review process, which the agency deemed a major amendment to the original filing.
The agency once again revised this date after the company submitted an expanded access protocol for the drug in nrSPMS at the FDA’s request. Further guidance from the FDA is expected by the end of the first quarter of 2026.
In the past six months, shares of Sanofi have inched up 1.1% compared with the industry’s increase of 20.4%.
Image Source: Zacks Investment Research
In July 2025, tolebrutinib was provisionally approved in the United Arab Emirates for the treatment of nrSPMS and to slow disability accumulation independent of relapse activity in adults. A regulatory filing seeking approval for tolebrutinib for a similar indication is currently under review in the European Union.
SNY's Recent Hurdles With Tolebrutinib Studies
Earlier this month, Sanofi announced that the phase III PERCEUS study, which evaluated tolebrutinib in patients with primary progressive multiple sclerosis (PPMS), did not meet the primary endpoint, in delaying time to onset of six-month composite confirmed disability progression versus placebo.
However, the safety profile of tolebrutinib was similar to that seen with previously conducted studies on the candidate.
Following this, Sanofi decided not to pursue further development of tolebrutinib in PPMS — an area that represents 10% of the overall multiple sclerosis (MS) patient population.
In 2022, the FDA placed a partial clinical hold on Sanofi’s phase III studies on tolebrutinib in MS and myasthenia gravis (MG) indications after the regulatory agency identified cases of drug-induced liver injury in some study participants who were treated with the drug.
The MG studies on tolebrutinib were eventually discontinued in 2022 after careful evaluation of the emerging competitive treatment landscape.
Gets EU Nod for Wayrilz
In a separate press release, Sanofi announced that the European Commission has approved Wayrilz (rilzabrutinib), a novel BTK inhibitor, as a new treatment for immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments.
The approval in the EU was expected, as in October, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) rendered a positive opinion recommending the approval of Wayrilz for the given indication.
The approval in the EU was based on data from the pivotal phase III LUNA 3 study, which showed that treatment with Wayrilz led to a positive impact on sustained platelet counts and other ITP symptoms, thus meeting both the primary and secondary endpoints.
The FDA approved Wayrilz for the treatment of persistent or chronic ITP in adult patients who have had an insufficient response to a previous treatment in August 2025.
In the past 60 days, estimates for CorMedix’s 2025 earnings per share (EPS) have increased from $1.85 to $2.87. EPS estimates for 2026 have moved up from $2.49 to $2.88 during the same period. CRMD stock has decreased 23.8% in the past six months.
CorMedix’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 27.04%.
In the past 60 days, estimates for Castle Biosciences’ loss per share have narrowed from 64 cents to 34 cents for 2025. During the same time, loss per share estimates for 2026 have narrowed from $1.82 to $1.06. In the past six months, shares of CSTL have rallied 109.9%.
Castle Biosciences’ earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, the average surprise being 66.11%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
FDA Issues CRL to SNY's Regulatory Filing for Multiple Sclerosis Drug
Key Takeaways
Sanofi (SNY - Free Report) announced that the FDA has issued a complete response letter (CRL) to its new drug application (NDA), seeking approval for its investigational Bruton's tyrosine kinase (BTK) inhibitor, tolebrutinib. The NDA sought approval for tolebrutinib to treat adult patients with non-relapsing secondary progressive multiple sclerosis (nrSPMS).
More on FDA’s CRL for Sanofi’s Tolebrutinib
The FDA’s latest CRL for tolebrutinib does not come as a surprise, as earlier this month, the regulatory body extended the review timeline for tolebrutinib in nrSPMS for the second time this year.
Earlier this year, the FDA had extended the review period for Sanofi’s NDA for tolebrutinib in nrSPMS by three months. The FDA was initially expected to give its decision by Sept. 28, 2025. However, this date was extended by an additional three months to Dec. 28 after Sanofi’s submission of additional analyses during the review process, which the agency deemed a major amendment to the original filing.
The agency once again revised this date after the company submitted an expanded access protocol for the drug in nrSPMS at the FDA’s request. Further guidance from the FDA is expected by the end of the first quarter of 2026.
In the past six months, shares of Sanofi have inched up 1.1% compared with the industry’s increase of 20.4%.
Image Source: Zacks Investment Research
In July 2025, tolebrutinib was provisionally approved in the United Arab Emirates for the treatment of nrSPMS and to slow disability accumulation independent of relapse activity in adults. A regulatory filing seeking approval for tolebrutinib for a similar indication is currently under review in the European Union.
SNY's Recent Hurdles With Tolebrutinib Studies
Earlier this month, Sanofi announced that the phase III PERCEUS study, which evaluated tolebrutinib in patients with primary progressive multiple sclerosis (PPMS), did not meet the primary endpoint, in delaying time to onset of six-month composite confirmed disability progression versus placebo.
However, the safety profile of tolebrutinib was similar to that seen with previously conducted studies on the candidate.
Following this, Sanofi decided not to pursue further development of tolebrutinib in PPMS — an area that represents 10% of the overall multiple sclerosis (MS) patient population.
In 2022, the FDA placed a partial clinical hold on Sanofi’s phase III studies on tolebrutinib in MS and myasthenia gravis (MG) indications after the regulatory agency identified cases of drug-induced liver injury in some study participants who were treated with the drug.
The MG studies on tolebrutinib were eventually discontinued in 2022 after careful evaluation of the emerging competitive treatment landscape.
Gets EU Nod for Wayrilz
In a separate press release, Sanofi announced that the European Commission has approved Wayrilz (rilzabrutinib), a novel BTK inhibitor, as a new treatment for immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments.
The approval in the EU was expected, as in October, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) rendered a positive opinion recommending the approval of Wayrilz for the given indication.
The approval in the EU was based on data from the pivotal phase III LUNA 3 study, which showed that treatment with Wayrilz led to a positive impact on sustained platelet counts and other ITP symptoms, thus meeting both the primary and secondary endpoints.
The FDA approved Wayrilz for the treatment of persistent or chronic ITP in adult patients who have had an insufficient response to a previous treatment in August 2025.
SNY's Zacks & Stocks to Consider
Sanofi currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are CorMedix (CRMD - Free Report) and Castle Biosciences (CSTL - Free Report) , both sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for CorMedix’s 2025 earnings per share (EPS) have increased from $1.85 to $2.87. EPS estimates for 2026 have moved up from $2.49 to $2.88 during the same period. CRMD stock has decreased 23.8% in the past six months.
CorMedix’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 27.04%.
In the past 60 days, estimates for Castle Biosciences’ loss per share have narrowed from 64 cents to 34 cents for 2025. During the same time, loss per share estimates for 2026 have narrowed from $1.82 to $1.06. In the past six months, shares of CSTL have rallied 109.9%.
Castle Biosciences’ earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, the average surprise being 66.11%.